Thomas Bachelot

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2810030/publications.pdf

Version: 2024-02-01

53	9,200	218677	144013
papers	citations	26 h-index	57 g-index

63	63	63	9368
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Everolimus in Postmenopausal Hormone-Receptorâ€“Positive Advanced Breast Cancer. New England Journal of Medicine, 2012, 366, 520-529.	27.0	2,474
2	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. New England Journal of Medicine, 2016, 375, 1738-1748.	27.0	1,390
3	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 2020, 382, 597-609.	27.0	789
4	Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study. Journal of Clinical Oncology, 2012, 30, 2718-2724.	1.6	630
5	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncology, The, 2013, 14, 64-71.	10.7	622
6	Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period. Journal of Clinical Oncology, 2004, 22, 3302-3308.	1.6	389
7	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncology, The, 2014, 15, 267-274.	10.7	351
8	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. Journal of Clinical Oncology, 2020, 38, 2610-2619.	1.6	331
9	Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2018, 19, 87-100.	10.7	307
10	Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer. JAMA Oncology, 2016, 2, 1557.	7.1	242
11	Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. European Journal of Cancer, 2018, 96, 17-24.	2.8	211
12	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: Results From BOLERO-2. Journal of Clinical Oncology, 2016, 34, 419-426.	1.6	203
13	Treatment strategies for breast cancer brain metastases. British Journal of Cancer, 2021, 124, 142-155.	6.4	117
14	Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. British Journal of Cancer, 2019, 121, 991-1000.	6.4	113
15	Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncology, The, 2015, 16, 1700-1710.	10.7	108
16	A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2020, 26, 5310-5319.	7.0	102
17	Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. Breast Cancer Research and Treatment, 2016, 157, 307-318.	2.5	101
18	MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Breast Cancer Research, 2015, 17, 13.	5.0	69

#	Article	IF	Citations
19	Bevacizumab and Paclitaxel for Breast Cancer Patients with Central Nervous System Metastases: A Case Series. Clinical Breast Cancer, 2009, 9, 118-121.	2.4	58
20	Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study. European Journal of Cancer, 2013, 49, 2621-2632.	2.8	53
21	Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer. JAMA Oncology, 2018, 4, 977.	7.1	48
22	Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MKâ€2206 with an aromatase inhibitor. International Journal of Cancer, 2013, 133, 1589-1602.	5.1	42
23	Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis. Breast Cancer Research and Treatment, 2014, 143, 125-133.	2.5	33
24	A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers. Molecular Oncology, 2014, 8, 1441-1457.	4.6	32
25	TIF1Î³ interferes with TGFÎ²1/SMAD4 signaling to promote poor outcome in operable breast cancer patients. BMC Cancer, 2015, 15, 453.	2.6	28
26	mTOR inhibitors in advanced breast cancer: Ready for prime time?. Cancer Treatment Reviews, 2013, 39, 742-752.	7.7	27
27	Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptorâ€“Positive, HER2-Negative Early Breast Cancer. Translational Oncology, 2016, 9, 114-123.	3.7	27
28	Feasibility and Health Benefits of an Individualized Physical Activity Intervention in Women With Metastatic Breast Cancer: Intervention Study. JMIR MHealth and UHealth, 2020, 8, e12306.	3.7	27
29	Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort. Breast, 2020, 52, 50-57.	2.2	25
30	Health-related quality of life and disease symptoms in postmenopausal women with HR⁺, HER2^{â^'}advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. Current Medical Research and Opinion, 2013, 29, 1463-1473.	1.9	24
31	Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive nonâ€metastatic breast cancer. British Journal of Clinical Pharmacology, 2016, 81, 941-948.	2.4	24
32	A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2â^' advanced breast cancer. Cancer Treatment Reviews, 2015, 41, 94-104.	7.7	22
33	Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients. Oncotarget, 2017, 8, 83570-83584.	1.8	18
34	A Personalized Physical Activity Program With Activity Trackers and a Mobile Phone App for Patients With Metastatic Breast Cancer: Protocol for a Single-Arm Feasibility Trial. JMIR Research Protocols, 2018, 7, e10487.	1.0	18
35	Physical activity preferences before and after participation in a 6â€month physical activity intervention among women with metastatic breast cancer. European Journal of Cancer Care, 2020, 29, e13169.	1.5	16
36	Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer. Clinical Cancer Research, 2021, 27, 418-428.	7.0	16

#	Article	IF	Citations
37	Sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer: results from the ABLE feasibility trial. Breast Cancer Research and Treatment, 2021, 188, 601-613.	2.5	16
38	Assessment of the efficacy of successive endocrine therapies in hormone receptorâ€“positive and HER2-negative metastatic breast cancer: a real-life multicentre national study. European Journal of Cancer, 2019, 118, 131-141.	2.8	11
39	Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Primary Breast Cancer. Journal of Clinical Oncology, 2022, 40, 3699-3708.	1.6	11
40	Impact of Physical Activity on Oxidative Stress Markers in Patients with Metastatic Breast Cancer. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-9.	4.0	9
41	A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). European Journal of Cancer, 2021, 158, 169-180.	2.8	9
42	Individualized Prediction of Menses Recovery After Chemotherapy for Early-stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials. Clinical Breast Cancer, 2019, 19, 63-70.	2.4	8
43	Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer. Scientific Reports, 2020, 10, 10757.	3.3	8
44	Optimal duration of adjuvant chemotherapy for high-risk node-negative (Nâ€“) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106). European Journal of Cancer, 2017, 79, 166-175.	2.8	5
45	Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer. Current Opinion in Oncology, 2020, 32, 555-560.	2.4	4
46	Rapalog-Mediated Repression of Tribbles Pseudokinase 3 Regulates Pre-mRNA Splicing. Cancer Research, 2020, 80, 2190-2203.	0.9	4
47	Targeted treatments for breast cancer: a step forward. Lancet Oncology, The, 2013, 14, 438-439.	10.7	3
48	Brain metastases from HER2-positive breast cancer â€“ Authors' reply. Lancet Oncology, The, 2013, 14, e3-e4.	10.7	2
49	Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210770.	3.2	2
50	Reply to J.-H. Choi et al. Journal of Clinical Oncology, 2013, 31, 511-511.	1.6	1
51	PI3K targeting in breast cancer: the end of the beginning?. Lancet Oncology, The, 2016, 17, 696-697.	10.7	1
52	Medical treatment for active breast cancer brain metastases. Lancet Oncology, The, 2022, , .	10.7	1
53	Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment, 2022, 191, 191-207.	2.5	0